Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. see more

OTCQX:MRVFF - Post Discussion

Nuvo Pharmaceuticals Inc > Vimovo Patents
View:
Post by midard on Nov 09, 2019 8:59am

Vimovo Patents

Dr. Reddy’s failed to persuade a New Jersey judge to dismiss a patent-infringement lawsuit brought by Horizon and Nuvo over a proposed copycat of Vimovo, used to treat arthritis.

https://news.bloomberglaw.com/pharma-and-life-sciences/judge-denies-dr-reddys-request-to-drop-case-on-vimovo-patents
Comment by lscfa on Nov 09, 2019 10:37am
Great news.....
Comment by ValueCap on Nov 09, 2019 5:50pm
Wow! Thats huge. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities